GBS
GBS Inc.·Healthcare
0.47
1.581%(−0.01)
Close PriceLast Updated: — ET
52W L: $0.3652W H: $2.89
GBS NEWS
gurufocus.com
17h ago
Hansa Biopharma reports positive efficacy and safety results from Idefirix® European post authorization study in kidney transplantation
Hansa Biopharma reports positive efficacy and safety results from Idefirix European post authorization study in kidney transplantation
gurufocus.com
1d ago
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026
Hansa Biopharma Announces Late-Breaking Abstract from ConfIdeS Phase 3 Trial Selected for Oral Presentation at ATC 2026 PR News
gurufocus.com
May 20
Is Intuit (INTU) Undervalued After Q3 FY26 Earnings? EPS $11.09 Beats Estimates, Revenue $8.56B Misses; GF Score 87/100, 51.2% Undervalued
Filing date: May 20, 2026GAAP diluted EPS was $11.09, which is higher than the estimated EPS of $10.65.Revenue was $8,558 million, which is below the estimated
gurufocus.com
May 19
Hansa Biopharma enters into €115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA
Hansa Biopharma enters into â¬115 million licensing agreement with SERB Pharmaceuticals for IDEFIRIX in Europe and MENA PR New
globenewswire.com
May 11
110 Years. 110 Stories. 110 Reasons to Raise Awareness for GBS
CONSHOHOCKEN, Pa., May 11, 2026 (GLOBE NEWSWIRE) -- May is GBS|CIDP Awareness Month and this year marks 110 years since the discovery of Guillain-Barré syndrome (GBS), which was first identified and named in 1916 by French neurologists Georges Guillain, Jean Alexandre Barré, and André Strohl.
gurufocus.com
Apr 1
Larry Robbins Increases Stake in DXC Technology Co
Transaction Overview On March 20, 2026, Larry Robbins (Trades, Portfolio), through Glenview Capital Management, increased the firm's stake in DXC Technology Co
